In 2024 we confirmed our commitment to R&D, by strengthening our collaborations with the most prestigious neuroinflammation research groups and investing 10% of our turnover in research.
This drive for innovation has always been a key value of Epitech Group and has resulted in a current portfolio of 392 patents, a number that has doubled in the last 5 years.
«The patents covering the use of aliamides and technologies to make them bioavailable» comments Epitech Group CEO Raffaella della Valle, «are the result of a commitment Francesco della Valle undertook over 30 years ago: a commitment to support scientific research on innovative molecules, capable of protecting against inflammatory damage and promoting physiological balance, according to the same modulatory mechanisms implemented by the body. With 116 published clinical studies and 49 ongoing, we aim to define new strategies for controlling neuroinflammatory processes common to different pathological conditions, from neurological and degenerative ones, to uro-gynecological, osteoarticular and metabolic ones. The same General Meeting held last January was an opportunity to deepen neuro-urological clinical aspects, together with the launch of a new product for chronic male pelvic pain. But there are many other open fronts in the clinical and preclinical research settings, such as studies investigating the effects of new generation molecules, which are yielding very promising results, encouraging us to continue with enthusiasm and even with a bit of ambition».
